Skip to main content
. 2019 Jun 20;90(11):1244–1250. doi: 10.1136/jnnp-2018-320071

Table 1.

Baseline characteristics of study population.

BoNT n=25 Placebo n=23
Age, year (median; IQR) 50.0 (40.0; 61.5) 54.0 (37.0; 57.0)
Gender, n (%)
 Male 14 (56) 14 (61)
Duration of disease, year (median; IQR) 5.0 (2.1; 13.4) 5.3 (2.2; 9.0)
Fahn and Williams diagnostic criteria, n (%)
 Clinically definite 18 (72.0) 16 (69.6)
 Clinically probable 7 (28.0) 7 (30.4)
Additional phenomenology based on PMDRS, n (%)
 Dystonia 12 (48.0) 10 (43.5)
 Tic 3 (12.0) 2 (8.7)
Distribution of jerks/tremor, n (%)
 Abdomen 12 (48.0) 11 (47.8)
 Extremity 13 (52.0) 12 (52.2)
Education level, n (%)
 Primary school 1 (4.0) 2 (8.7)
 Lower education 4 (16.0) 3 (13.0)
 Medium education/higher school 11 (44.0) 12 (52.2)
 Higher education/university 9 (36.0) 6 (26.1)
 Unemployed 17 (68.0) 13 (56.5)
 Disease-related* 13 (52.0) 11 (47.8)
Clinical neurophysiology, n (%)† 13 (52.0) 14 (60.9)
 Pre-movement potential 11 (61.5) 11 (57.1)
Previous treatment, n (%)‡ 21 (84.0) 22 (95.7)
 Rehabilitation 4 (16.0) 5 (21.7)
 Physiotherapy 8 (34.8) 9 (36.0)
 Psychotherapy 5 (20.0) 7 (30.4)
 Other§ 17 (68.0) 17 (73.9)

*Other forms of financial income included retirement (n=4 BoNT vs n=1 placebo), study (n=1 placebo).

†EEG-EMG with backaveraging could not be performed in the whole population.

‡More than one category could apply per patient.

§Other treatment includes acupuncture, homeopathic treatment, alternative medicine, hypnosis, benzodiazepines, Selective Serotonin Reuptake Inhibitors (SSRIs), anti-epileptics, dopamine-agonists.

BoNT, botulinum neurotoxin; EEG, electroencephalogram; EMG, electromyogram; PMDRS, Psychogenic Movement Disorder Rating Scale.